Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide in Osteoarthritis Knee Pain and Obesity/Overweight
NCT07353931Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Peptides
- Countries
- 13
01
Overview
A Phase 3 trial of eloralintide in osteoarthritis (OA), obesity, sponsored by Eli Lilly and Company. Started Feb 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
osteoarthritis (OA)obesity
Beyond the preview
Go deeper on NCT07353931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353931.